natgillin/translations-raw huggingface dataset:
A minor and transient increase in rectal temperature (0.8 °C on average, and up to 1.0 °C individually) may very commonly occur 4 hours post vaccination in PRRS virus-naïve gilts and sows in the first half of gestation.
Zelo pogosto se lahko pojavi manjše in prehodno zvišanje rektalne temperature (povprečno 0,8 °C, v posameznih primerih tudi do 1,0 °C) v 4 urah po cepljenju pri na PRRS virus imunološko naivnih mladicah in plemenskih svinjah v prvi polovici brejosti.
PACKAGE LEAFLET: Suvaxyn PRRS MLV lyophilisate and solvent for suspension for injection for pigs
NAVODILO ZA UPORABO: Suvaxyn PRRS MLV liofilizat in vehikel za suspenzijo za injiciranje za prašiče
A minor and transient increase in rectal temperature (0.2 °C on average, and up to 1.0 °C individually) may very commonly occur 4 hours post vaccination in pre-breeding PRRS virus-naïve gilts and sows.
Zelo pogosto se lahko pojavi manjše in prehodno zvišanje rektalne temperature (povprečno 0,2 °C, v posameznih primerih tudi do 1,0 °C) v 4 urah po cepljenju pri na PRRS virus imunološko naivnih mladicah in plemenskih svinjah pred brejostjo.
Marketing authorization holder and manufacturer responsible for batch release:
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za sproščanje serij: Zoetis Belgium SA
After the administration of a 10-fold overdose to non-PRRS virus-naïve gilts and sows in the second half of pregnancy a transient increase in rectal temperature (0.3 °C on average, and up to 0.6 °C individually) occurred 4 hours post vaccination.
Pri na PRRS virus imunološko ne-naivnih mladicah in plemenskih svinjah v drugi polovici brejosti se je po aplikaciji 10-kratnega prekomernega odmerka pojavilo prehodno zvišanje rektalne temperature
A transient increase in rectal temperature (0.3 ºC on average, and up to 1.2 °C individually) very commonly occurred 24 hours post vaccination.
(povprečno 0,3 °C, v posameznih primerih tudi do 1,2 °C) v 24 urah po cepljenju.
Ph. Eur.
Rp-Vet.
The administration of a 10-fold overdose to PRRS virus-naïve pre-breeding or pregnant gilts and sows in the first or second half of pregnancy induced similar adverse reactions as those described under section 6.
kratnega odmerka pri na PRRS virus imunološko naivnih mladicah in plemenskih svinjah pred brejostjo ali v prvi ali drugi polovici brejosti.
Suvaxyn PRRS MLV solvent for suspension for injection for pigs
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Suvaxyn PRRS MLV liofilizat za suspenzijo za injiciranje za prašiče
The educational materials should be submitted at the same time as the variation of product information application.
Izobraževalna gradiva je treba predložiti sočasno z vlogo za spremembo informacij o zdravilu.
12 January 2015
12. januarja 2015
Implementation of the agreement by the Member States (submission of the variation to implement the changes to the product information by the Marketing Authorisation Holder):
Izvajanje sporazuma s strani držav članic (predložitev vloge za spremembo za vključitev sprememb v informacije o zdravilu s strani imetnika dovoljenja za promet z zdravilom):
November 2014 CMDh meeting
zasedanje skupine CMDh novembra 2014
Use in adults, including the elderly
Uporaba pri odraslih, vključno s starejšimi
Continue with the next dose as planned.
Nadaljujte z naslednjim odmerkom, kot je predvideno.
• Wash your hands before you start.
• Preden začnete, si umijte roke.
Use the medicine at around the same time each day.
Zdravilo uporabljajte vsak dan ob približno istem času.
Over half were aged ≥ 65 years.
Več kot polovica je bila stara ≥ 65 let.
The median age of study participants was 65.5 years (range 18 to 91 years).
Mediana starost udeležencev študije je bila 65,5 leta (razpon od 18 do 91 let).
Do not put in any more drops until it is time for your next regular dose.
Kapljic ne uporabljajte več, dokler ni čas za vaš naslednji redni odmerek.
Netarsudil 0.02% Once daily
Netarsudil 0,02 % enkrat na dan
MARKETING AUTHORISATION NUMBER(S) EU/1/19/1400/001
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/1/19/1400/001
Clear solution, pH 5 (approximately).
Bistra raztopina, pH 5 (približno).
Studies in animal and man suggest that the main mechanism of action is increased trabecular outflow.
Študije pri živalih in ljudeh kažejo, da je glavni mehanizem delovanja povečan trabekularni odtok.
SPECIAL STORAGE CONDITIONS Store in a refrigerator until opened.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v hladilniku do odprtja.
If the pressure in the eye is too high, it can damage your sight.
Če je tlak v očeh previsok, lahko okvari vaš vid.
Patients should be monitored in case of prolonged use.
V primeru dolgotrajne uporabe je treba bolnike spremljati.
Treatment of an overdose would include supportive and symptomatic therapy.
Zdravljenje prevelikega odmerjanja bi vključevalo podporno in simptomatsko zdravljenje.
Cornea verticillata occurred in approximately 20% of the patients in controlled Phase 3 clinical studies.
Cornea verticillata se je pojavila pri približno 20 % bolnikov v nadzorovanih kliničnih študijah 3. faze.
This reaction did not result in any apparent visual functional changes in patients.
Ta učinek pri bolnikih ni povzročil opaznih funkcionalnih sprememb vida.
It could infect the drops.
Tako bi lahko okužili kapljice.
Long-term studies in animals have not been performed to evaluate the carcinogenic potential of netarsudil.
Dolgoročnih študij pri živalih za ovrednotenje kancerogenega potenciala netarsudila niso izvedli.
Do not use this medicine after the expiry date which is stated on the bottle and the carton after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake „EXP“.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
If you stop using Rhokiinsa the pressure in your eye will not be controlled which could lead to loss of sight.
Če prenehate uporabljati zdravilo Rhokiinsa, tlak v vašem očesu ne bo nadzorovan, kar lahko privede do izgube vida.
• If you need to use the drops in both eyes, repeat the steps for your other eye while you have the bottle open.
• Če morate kapljice uporabljati v obeh očesih, zgornje korake ponovite še za drugo oko, plastenka pa naj pri tem ostane odprta.
If one dose is missed, treatment should continue with the next dose in the evening.
Če bolnik izpusti en odmerek, naj zdravljenje nadaljuje z naslednjim večernim odmerkom.
If you are using other eye drops, wait at least five minutes after using them and then use Rhokiinsa.
Če uporabljate še druge kapljice za oko, po njihovi uporabi počakajte vsaj pet minut, nato pa uporabite zdravilo Rhokiinsa.
The drop will go in here (Picture 1).
To je mesto, kamor je treba dati kapljico (slika 1).
If netarsudil is to be used concomitantly with other topical ophthalmic medicinal products, each medicinal product should be administered at least five (5) minutes apart.
Če se netarsudil uporablja sočasno z drugimi topičnimi oftalmičnimi zdravili, je treba posamezna zdravila uporabiti s presledkom vsaj pet (5) minut.
The efficacy of netarsudil has not been studied beyond 12 months.
Učinkovitosti netarsudila niso preučevali za obdobje, daljše od 12 mesecev.
Store in a refrigerator (2°C - 8°C) until opened.
Shranjujte v hladilniku (2 °C-8 °C) do odprtja.
Do not use a double dose to make up for a forgotten dose.
Ne uporabite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
• Pull down your lower eyelid with a clean finger to form a ‘pocket' between the eyelid and your eye.
• S čistim prstom povlecite spodnjo veko, tako da ustvarite „žepek“ med veko in očesom.
However, there was a relatively small proportion of subjects with moderate or severe hyperaemia who discontinued treatment because of this adverse reaction (6.0% in Phase 3 clinical studies).
Vendar pa je razmeroma majhen delež preskušancev z zmerno ali hudo hiperemijo zaradi tega neželenega učinka prekinil zdravljenje (6,0 % v kliničnih študijah 3. faze).
If you are using eye ointments, these should be used last.
Če uporabljate mazila za oko, jih uporabite nazadnje.
Twice a day dosing is not well tolerated and is not recommended.
Učinki na očeh Odmerjanja dvakrat dnevno bolniki ne prenašajo dobro in ga ne priporočamo.
Subjects with known contraindications or hypersensitivity to timolol were excluded from the studies.
Preskušanci z znanimi kontraindikacijami ali preobčutljivostjo za timolol so bili iz študij izključeni.
Do not use Rhokiinsa if you are pregnant unless your doctor still recommends it.
Zdravila Rhokiinsa ne uporabljajte, če ste noseči, razen če vam ga zdravnik vseeno priporoči.
If transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.
Če ima po vkapanju kapljic bolnik začasno zamegljen vid, mora počakati, da se mu vid zbistri, preden sme voziti ali upravljati stroje.
Rhokiinsa should not be used in children and teenagers under 18 years of age as it has only been studied in adults.
Zdravilo Rhokiinsa se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let, ker ga v teh starostnih skupinah niso preučevali.
There are no data on the effects of netarsudil on male or female fertility.
Ni podatkov o učinkih netarsudila na plodnost moških ali žensk.
Approximately 75% of subjects included in the netarsudil treatment groups of Phase 3 studies were Caucasian and 24% Black or African American.
Približno 75 % preskušancev, vključenih v skupine, zdravljene z netarsudilom, v študijah 3. faze je bilo belcev, 24 % pa črne rase oz. Afroameričanov.
Each bottle contains 2.5 ml of the medicine and each pack contains one bottle with a screw-cap.
Ena plastenka vsebuje 2,5 ml zdravila in vsako pakiranje vsebuje eno plastenko z navojnim pokrovčkom.
The incidence of cornea verticillata was higher in certain subpopulations: elderly (≥65 years) versus non-elderly (24.8 vs. 15.9%); males versus females (24.4 vs. 18.4%) and in white versus other races (25.6 vs. 7.0%).
Pojavnost cornee verticillate je bila večja v določenih podpopulacijah: pri starejših (≥ 65 let) v primerjavi z mlajšimi (24,8 v primerjavi s 15,9 %); pri moških v primerjavi z ženskami (24,4 v primerjavi z 18,4 %) in pri belcih v primerjavi z drugimi rasami (25,6 v primerjavi s 7,0 %).
• Only put one drop into your eye each time.
• V posamezno oko vsakič kapnite samo eno kapljico.
• General side effects: Headache
• Splošni neželeni učinki: glavobol
The majority of cornea verticillata resolved upon discontinuation of treatment.
Večina primerov cornee verticillate je izzvenela po prekinitvi zdravljenja.
It is therefore recommended to dose netarsudil once daily.
Zato se priporoča odmerjanje netarsudila enkrat na dan.
Carton containing 1 bottle.
Škatla vsebuje eno plastenko.
decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Rhokiinsa therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja ali prenehanjem/prekinitvijo zdravljenja z zdravilom Rhokiinsa, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Timolol 0.5% twice daily Difference (95% CI) Netarsudil - Timolol
Razlika (95-odstotni IZ) netarsudil - timolol
With the exception of the incidence of cornea verticillata, no other difference in safety profile was observed between races or age groups (see section 4.8).
Z izjemo pojavnosti cornee verticillate med skupinami različnih ras ali starostnimi skupinami niso opazili drugih razlik v varnostnem profilu (glejte poglavje 4.8).
The safety of netarsudil has been evaluated in clinical studies, including four well-controlled Phase 3 studies.
Varnost netarsudila so ocenili v kliničnih študijah, vključno s štirimi dobro nadzorovanimi študijami
Reactions are classified according to the convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) or not known (cannot be estimated from the available data).
< 1/100), redki (od ≥ 1/10 000 do < 1/1 000), zelo redki (< 1/10 000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Marketing Authorisation Holder and Manufacturer Aerie Pharmaceuticals Ireland, Limited Athlone Business and Technology Park, Dublin Road,
Imetnik dovoljenja za promet z zdravilom in izdelovalec Aerie Pharmaceuticals Ireland, Limited Athlone Business and Technology Park, Dublin Road,
The most common ocular adverse reaction observed is conjunctival hyperemia which was reported in 51% of patients.
Najpogostejši opaženi neželeni učinek je hiperemija veznice, o kateri so poročali pri 51 % bolnikov.
The safety and efficacy of Rhokiinsa in children below the age of 18 years have not been established.
Pediatrična populacija Varnost in učinkovitost zdravila Rhokiinsa pri otrocih in mladostnikih, starih manj kot 18 let, še nista bili dokazani.
Only use Rhokiinsa for your eyes (ocular use).
Zdravilo Rhokiinsa uporabljajte samo za oči (okularna uporaba).
• Hold the bottle, pointing down, between your thumb and fingers.
• Plastenko držite obrnjeno navzdol med palcem in ostalimi prsti.
Twice a day dosing was also associated with a higher discontinuation rate due to adverse reactions (53.8%) during a 12-month study.
Dvakrat dnevno odmerjanje je bilo v 12-mesečni študiji povezano tudi z večjo stopnjo prekinitve zdravljenja zaradi neželenih učinkov (53,8 %).
What Rhokiinsa is and what it is used for What you need to know before you use Rhokiinsa How to use Rhokiinsa
Kaj je zdravilo Rhokiinsa in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Rhokiinsa Kako uporabljati zdravilo Rhokiinsa
INFORMATION IN BRAILLE Rhokiinsa
PODATKI V BRAILLOVI PISAVI Rhokiinsa
Unopened bottles: Store in a refrigerator (2°C - 8°C).
Neodprte plastenke: shranjujte v hladilniku (2 °C-8 °C).
If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.
Če imate po uporabi tega zdravila nenormalen občutek v očesu, vas zbada ali imate bolečine v očesu, se pogovorite z zdravnikom.
• Do not touch the dropper with your fingers when opening or closing the bottle.
• Pri odpiranju ali zapiranju plastenke se kapalne konice ne dotikajte s prsti.
The efficacy and safety of netarsudil in subjects with compromised corneal epithelium or co-existing ocular pathologies e.g. pseudoexfoliation and dispersion pigment syndrome has not been established.
Učinkovitost in varnost netarsudila pri preskušancih s prizadetim roženičnim epitelijem ali sočasnimi očesnimi patologijami, npr. psevdoeksfoliacijo in pigmentnim disperzijskim sindromom, nista bili dokazani.
Benzalkonium chloride, boric acid, mannitol, sodium hydroxide, water for injections.
Benzalkonijev klorid, borova kislina, manitol, natrijev hidroksid, voda za injekcije.
Intravenous administration of netarsudil mesylate to pregnant rats and rabbits during organogenesis did not produce adverse embryofetal effects at clinically relevant systemic exposures.
Intravensko dajanje netarsudilijevega mesilata brejim podganam in kuncem med organogenezo pri klinično pomembnih sistemskih izpostavljenostih ni povzročila neželenih embriofetalnih učinkov.
What Rhokiinsa is and what it is used for
Kaj je zdravilo Rhokiinsa in za kaj ga uporabljamo
Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye).
Benzalkonijev klorid lahko povzroči tudi draženje oči, zlasti če imate suhe oči ali težave z roženico (prosojni, sprednji del očesa).
Efficacy was also investigated in patients with baseline IOP ≥25 mmHg and <30 mmHg.
Učinkovitost so preučevali tudi pri bolnikih z izhodiščnim IOP ≥ 25 mmHg in < 30 mmHg.
No data on potential interactions specific to netarsudil is currently available (see section 4.5).
Trenutno ni na voljo podatkov o morebitnem medsebojnem delovanju, specifičnem za netarsudil (glejte poglavje 4.5).
Throw away the bottle 4 weeks after first opening to prevent infections and use a new bottle.
Da preprečite okužbe, plastenko zavrzite 4 tedne po prvem odprtju in uporabite novo.
- The other excipients are benzalkonium chloride (see section 2 under ‘Rhokiinsa contains benzalkonium chloride'), mannitol, boric acid, sodium hydroxide and water for injections.
- Druge sestavine zdravila so benzalkonijev klorid (glejte poglavje 2 „Zdravilo Rhokiinsa vsebuje benzalkonijev klorid“), manitol, borova kislina, natrijev hidroksid in voda za injekcije.
These studies also suggest that netarsudil lowers IOP by reducing episcleral venous pressure.
Te študije kažejo tudi, da netarsudil znižuje IOP z zniževanjem episkleralnega venskega tlaka.
Animal studies with intravenous administration do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant exposures (see section 5.3).
Študije na živalih pri intravenski uporabi in klinično pomembnih izpostavljenostih ne kažejo neposrednih ali posrednih škodljivih učinkov na sposobnost razmnoževanja (glejte poglavje 5.3).
Rhokiinsa should not be used during pregnancy unless the clinical condition of the woman requires treatment with netarsudil.
Zdravilo Rhokiinsa se ne sme uporabljati med nosečnostjo, razen če je zdravljenje z netarsudilom potrebno zaradi kliničnega stanja ženske.
Netarsudil belongs to a group of medicines called “Rho kinase inhibitors”, which work to reduce the amount of fluid inside the eye and so lower its pressure.
Netarsudil spada v skupino zdravil, imenovanih „zaviralci Rho-kinaze“, ki zmanjšujejo količino tekočine v očesu in znižujejo njen tlak.
Opened bottle: 4 weeks after first opening the bottle.
Odprta plastenka: 4 tedni po prvem odprtju plastenke.
Conjunctival hyperaemia was the most frequently reported adverse reaction associated with netarsudil treatment in clinical trials and it is attributed to the vasodilation effect of the Rho kinase inhibitor drug class.
Hiperemija veznice je bila neželeni učinek, o katerem so najpogosteje poročali v povezavi z zdravljenjem z netarsudilom v kliničnih preskušanjih, pripisujejo pa ga vazodilatacijskemu učinku skupine zdravil zaviralcev Rho-kinaze.
The systemic exposures of netarsudil and its active metabolite, AR-13503, were evaluated in 18 healthy subjects after topical ocular administration of netarsudil once daily (one drop bilaterally in the morning) for 8 days.
Sistemsko izpostavljenost netarsudilu in njegovemu aktivnemu presnovku, AR-13503, so ovrednotili pri 18 zdravih preskušancih po topični očesni uporabi netarsudila enkrat na dan (po ena kapljica v obe očesi zjutraj) v obdobju osmih dni.
Continue to hold the bottle, ensuring that the tip doesn't come into contact with anything.
Plastenko še naprej držite in pazite, da se s kapalno konico ničesar ne dotaknete.
Treatment with Rhokiinsa should only be initiated by an ophthalmologist or a healthcare professional qualified in ophthalmology.
Zdravljenje z zdravilom Rhokiinsa sme uvesti samo oftalmolog ali zdravstveni delavec, usposobljen v oftalmologiji.
Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface and is known to discolour soft contact lenses.
Poročali so, da benzalkonijev klorid povzroča draženje oči, simptome suhega očesa ter lahko vpliva na solzni film in površino roženice, znano pa je tudi, da povzroči obarvanje mehkih kontaktnih leč.
Other medicines and Rhokiinsa Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Obvestite zdravnika ali farmacevta, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
After topical ocular dosing, netarsudil is metabolised by esterases in the eye to an active metabolite, AR-13503.
Po topični okularni uporabi se netarsudil presnovi z esterazami v očesu v aktivni presnovek AR-13503.
Conjunctival hyperaemia was typically mild in severity and sporadic.
Hiperemija veznice je bila praviloma blaga in sporadična.
Discontinuation rates due to adverse reactions were 19.3% for the netarsudil treatment group versus 1.7% for the timolol maleate group.
Stopnja prekinitve zdravljenja zaradi neželenih učinkov je bila 19,3 % v skupini, zdravljeni z netarsudilom, in 1,7 % v skupini, zdravljeni s timololijevim maleatom.
There are no or limited amount of data from the use of netarsudil in pregnant women.
Podatkov o uporabi netarsudila pri nosečnicah ni oziroma so omejeni.
Very common conjunctival hyperaemia1, cornea verticillata1, instillation site pain
Zelo pogosti hiperemija veznice1, cornea verticillata bolečina na mestu vkapanja
The recommended dose is one drop in the affected eye or eyes once a day in the evening.
Priporočeni odmerek je ena kapljica v obolelo oko enkrat na dan zvečer.
In pregnant rats, 0.3 mg/kg/day (1000 times the recommended ophthalmic dose) and higher showed increased postimplantation loss and reduced foetal viability.
Pri brejih podganah je odmerek 0,3 mg/kg/dan (1000-kratnik priporočenega oftalmičnega odmerka) in več povečal poimplantacijsko izgubo in zmanjšal viabilnost plodov.
Do not stop using Rhokiinsa without first speaking to your doctor.
Ne prenehajte jemati zdravila Rhokiinsa, ne da bi se o tem posvetovali z zdravnikom.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Warnings and precautions • Do not use Rhokiinsa more than once a day, as you may experience more side effects.
• Zdravila Rhokiinsa ne uporabljajte več kot enkrat na dan, saj se lahko pojavi več neželenih učinkov.
• Gently squeeze the bottle to release one drop of Rhokiinsa into your eye.
• Nežno stisnite plastenko in v oko kapnite eno kapljico zdravila Rhokiinsa.
Rhokiinsa has negligible influence on the ability to drive and use machines.
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo Rhokiinsa ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
PHARMACEUTICAL FORM Eye drops, solution (eye drops).
FARMACEVTSKA OBLIKA Kapljice za oko, raztopina (kapljice za oko).
Other ocular adverse reactions reported are: cornea verticillata (17%), instillation site pain (17%), and conjunctival haemorrhage (8%).
Drugi očesni neželeni učinki, o katerih so poročali, so: cornea verticillata (17 %), bolečina na mestu vkapanja (17 %) in krvavitev v veznico (8 %).
Instillation site erythema (8%), corneal staining (7%), blurred vision (6%), increased lacrimation (6%) and erythema of eyelid (5%) were also reported.
Poročali so tudi o eritemu na mestu vkapanja (8 %), obarvanju roženice (7 %), zamegljenem vidu (6 %), povečanem solzenju (6 %) in eritemu veke (5 %).
Patients should not instill more than one drop in the affected eye(s) each day.
Bolniki si v obolelo oko ne smejo dati več kot eno kapljico na dan.
It should be used with caution in dry eye patients and in patients where the cornea may be compromised.
Pri bolnikih s suhimi očmi in bolnikih, pri katerih je roženica lahko prizadeta, ga je treba uporabljati previdno.
Netarsudil dosed twice daily provided slightly larger IOP reductions, but had a less favorable safety profile as reflected in a higher rate and increased severity of ocular adverse reactions.
Netarsudil, ki so ga dajali dvakrat dnevno, je sicer nekoliko bolj znižal IOP, vendar je imel manj ugoden varnostni profil,
Netarsudil demonstrated clinically relevant reductions in IOP at all timepoints, however non-inferiority to timolol was not demonstrated in this population with baseline IOP ≥25 mmHg and <30 mmHg (Table 2).
Pri netarsudilu so dokazali klinično pomembno znižanje IOP pri vseh časovnih točkah, vendar neinferiornosti v tej populaciji z izhodiščnim IOP ≥ 25 mmHg in < 30 mmHg v primerjavi s timololom niso dokazali (preglednica 2).